The Board of Directors of Prolight Diagnostics AB (publ) resolves on a rights issue of units of approximately SEK 98.8 million and proposes a directed issue of shares of approximately SEK 20.9 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The […]
Prolight Diagnostics publishes half-year report, 2023
Financial overviewSecond quarter, 1 April – 30 June, Q2 2023 Group Net sales amounted to 0 (0). Other operating income amounted to kSEK 101 (2,311). The profit after tax amounted to kSEK -8,033 (-7,055). Earnings per share before and after dillution: SEK -0.03 (-0.03). Cash flow from current operations was kSEK -8,571 (-10,210). First half-year, […]
Prolight Diagnostics shows proof-of-performance for high-sensitive troponin
Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance on its single molecule detection system to reproducibly detect low levels of the troponin protein. These results pave the way for early detection and rule-out of heart attack, which could reduce healthcare costs and improve the quality of […]
Prolight Diagnostics publishes quarterly report Q1, 2023
Financial overviewFirst quarter Q1 2023 Group(figures in brackets only refer to March 2022 as the group was formed on 1 March 2022) Net sales amounted to 0. Other operating income amounted toKSEK 39 (1,298). The profit after tax amounted to kSEK –7,580 (-3,675) Earnings per share before and after dilution: SEK-0.03 (-0.02). Cash flow from […]
Prolight Diagnostics publishes year-end report 2022
Financial overviewFourth quarter Q4 2022 GroupFormed March 1, 2022 Other operating income amounted to kSEK 2,050. The profit after tax amounted to kSEK -2,809. Earnings per share before and after dilution: SEK -0.01. Cash flow from current operations was kSEK -5,436. Cash and cash equivalents amounted to kSEK 54,111 as of December 31, 2022. Fourth […]
Prolight Diagnostics shows proof-of-performance for high-sensitive immuno assay
Prolight Diagnostics (“Prolight”) today announced that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance that its high-sensitivity immunoassay is capable of reproducibly detecting low levels of specific proteins in a digital manner. “This is a very important step on our journey to develop a high-sensitivity assay for digitally detecting troponin. Such an […]
Prolight Diagnostics signs commercialisation agreement for PLD Micro Flex
Prolight Diagnostics AB today announces that it has signed a commercialisation agreement for its proprietary point-of-care (POC) platform PLD Micro Flex with its technology and development partner, The Technology Partnership plc (TTP), in Cambridge, UK. Under the agreement, TTP will pursue further development and ongoing external initiatives and discussions with the aim of securing an […]
Prolight Diagnostics AB acquires Psyros Diagnostics Ltd
Prolight Diagnostics AB has today signed an agreement to acquire UK-based Psyros Diagnostics Ltd for 65 MSEK (ca. £5.25M). Psyros Diagnostics has developed a ground-breaking single-molecule counting Point-of-Care (POC) technology. This patent-pending and multiplex-capable technology enables the measurement of biomarkers at extremely low concentrations (femtomolar 10-15) in approximately 10 minutes or less. “To our knowledge, […]
